RDPTF (Radiopharm Theranostics) Interest Expense: $-0.35 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Radiopharm Theranostics Interest Expense?

Radiopharm Theranostics RDPTF Interest Expense is $-0.35 Mil as of Jun. 2025. The stock has 5 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Radiopharm Theranostics's interest expense for the six months ended in Jun. 2025 was $ -0.04 Mil. Its interest expense for the trailing twelve months (TTM) ended in Jun. 2025 was $-0.35 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Radiopharm Theranostics's Operating Income for the six months ended in Jun. 2025 was $ -9.66 Mil. Radiopharm Theranostics's Interest Expense for the six months ended in Jun. 2025 was $ -0.04 Mil. Radiopharm Theranostics did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Radiopharm Theranostics  (OTCPK:RDPTF) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Radiopharm Theranostics's Interest Expense for the six months ended in Jun. 2025 was $-0.04 Mil. Its Operating Income for the six months ended in Jun. 2025 was $-9.66 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Jun. 2025 was $0.00 Mil.

Radiopharm Theranostics's Interest Coverage for the quarter that ended in Jun. 2025 is calculated as

Radiopharm Theranostics did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Radiopharm Theranostics Interest Expense Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Interest Expense Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Interest Expense
-6.57 -0.06 -0.43 -0.04

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Interest Expense Get a 7-Day Free Trial 0.28 -0.03 -0.40 -0.31 -0.04

Radiopharm Theranostics Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-0.35 Mil mean?
Radiopharm Theranostics (RDPTF) has a Interest Expense of $-0.35 Mil as of Jun. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Radiopharm Theranostics and its competitors.
Is Radiopharm Theranostics' Interest Expense too high?
Radiopharm Theranostics' current Interest Expense is $-0.35 Mil.
How does Radiopharm Theranostics' Interest Expense compare to VRTX and REGN?
Radiopharm Theranostics' Interest Expense of $-0.35 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Interest Expense is $-0.35 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (RDPTF) has a current Interest Expense of $-0.35 Mil. The current Interest Expense is $-0.35 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Radiopharm Theranostics (RDPTF), the current Interest Expense is $-0.35 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USARAD:Australia
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.